Wave Life Sciences Ltd. (WVE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to Wave Life Sciences' first quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you'll be given instructions for the question and answer session. Also, as a reminder, this conference call is being recorded today. I will now turn the call over to Kate Roush, Vice President of Corporate Affairs and Investor Relations. Thank you, Operator, and good morning to everyone on the call. Earlier this morning, we issued a press release outlining our first quarter 2026 earnings update. Joining me today with prepared remarks are Dr. Paul Bono, President and Chief Executive Officer, Dr. Eric Engelson, Chief Scientific Officer, Dr. Chris Wright, Chief Medical Officer, and Kyle Moran, Chief Financial Officer. The press release issued this morning is available on the investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul. Thanks, Kate. And good morning to everyone joining us on today's call. Coming into the year, we outlined our key priorities for 2026. Accelerating development of WVE007, our Inhibini GalNec siRNA program for obesity, and rapidly advancing our RNA editing portfolio led by WVE006 for AATD and followed by WVE00...